Keep knowledgeable with free updates
Merely signal as much as the Personal fairness myFT Digest — delivered on to your inbox.
Blackstone has cooled on collaborating in a joint takeover bid for eyecare firm Bausch + Lomb, jeopardising one of many largest leveraged buyouts in healthcare this 12 months, in accordance with folks accustomed to talks.
The personal fairness group in October teamed up with investor TPG to discover a bid for Bausch + Lomb. However Blackstone had subsequently balked on the frothy worth expectations of the vendor, the folks stated.
An public sale course of for Bausch + Lomb, which sells contact lenses, dry eye medicine and surgical ophthalmology tools, started earlier this 12 months as its closely indebted guardian firm Bausch Well being regarded to pay down debt.
Two folks near the talks stated Blackstone would most likely drop out of the consortium, decreasing the percentages of a deal. Talks have been ongoing and a deal might nonetheless be clinched if Bausch + Lomb was prepared to simply accept a lower cost or if TPG discovered one other personal fairness group to behave as companion on the deal, the folks added.
Negotiations between Bausch + Lomb and the consortium have been held as lately as the top of final week. Shares in Bausch + Lomb stood at simply over $20 at Tuesday’s shut, giving it an enterprise worth together with debt of greater than $11bn. Bausch + Lomb’s share worth had jumped 30 per cent since the Financial Times first reported in September that it had employed Goldman Sachs to run a gross sales course of. Nevertheless, the inventory fell greater than 9 per cent in after-hours buying and selling following the FT’s report on Blackstone’s reluctance to affix the bid.
Bausch + Lomb’s board — which incorporates hedge fund titan John Paulson and a consultant of activist investor Carl Icahn, who’re each main Bausch Well being shareholders — had been hoping for a suggestion at a sizeable premium to $20 a share to get a deal over the road, however the consortium of TPG and Blackstone pushed again at providing such a excessive worth.
The corporate is run by chief govt Brent Saunders, a well known dealmaker who pushed the $63bn sale of botox maker Allergan to pharma group AbbVie, and is a detailed ally of Icahn.
TPG already owns an eyecare enterprise — BVI Medical — and questions arose in due diligence about the way it might be efficiently mixed with Bausch + Lomb.
Some 88 per cent of Bausch + Lomb is owned by Bausch Well being, which has been battling a $21bn debt pile and a languishing share worth left over from when it was beforehand generally known as Valeant. Valeant got here underneath strain from buyers for accounting irregularities and a pricey acquisition spree.
Bausch Well being has been attempting to spin off Bausch + Lomb as a listed firm however the course of faltered as Bausch Well being collectors, together with Apollo International Administration, Elliott Administration and GoldenTree Asset Administration, fretted over the impression it might have on the guardian firm’s steadiness sheet.
Blackstone, TPG and Bausch + Lomb declined to remark.
Bausch + Lomb has posted 4 quarters of about 20 per cent year-on-year gross sales progress, and its administration is assured it could proceed to thrive even when a deal falls aside, two folks stated. The eyecare firm is projected by analysts to generate $872mn in earnings earlier than curiosity, taxes, depreciation and amortisation this 12 months on $4.7bn in revenues.
Bausch Well being, in the meantime, is going through issues about $10bn in debt that’s set to return due earlier than the top of 2027 — with the best precedence being a $2.4bn fixed-rate mortgage due subsequent 12 months.
